Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Go back to Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 0.54 -0.02 (3.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.56 | 52 Week High | $9.70 | |||
| Open | $0.53 | 52 Week Low | $2.78 | |||
| Day High | $0.56 | P/E | N/A | |||
| Day Low | $0.53 | EPS | $0.00 | |||
| Volume | 21,633 | |||||
